<< CCO HIV inPractice to provide critical information for the management of HIV/AIDS launched | Roche discloses the results of first Phase III clinical study using Taspoglutide >>
Read in | English | Norsk

CNS Response to present results from depression efficacy study at U.S. Psychiatric and Mental Health Congress

Published on October 29, 2009 at 2:43 AM · No Comments

CNS Response, Inc. (OTCBB: CNSO) announced that the company will present top-line results from its multi-site clinical trial next week at the U.S. Psychiatric and Mental Health Congress. "Referenced-EEG (rEEGĀ®) Efficacy Compared to Star*D for Patients with Depression Treatment Failure: First Look at Final Results," will be presented by Charles DeBattista, M.D. on Monday, November 2nd, at 3:45 to 6:45 p.m. The conference is being held at the Mandalay Bay South Convention Center in Las Vegas, NV.

Dr. DeBattista is Professor of Psychiatry and Behavioral Health Sciences at Stanford University School of Medicine, and Director of the Depression and Psychopharmacology Clinic at Stanford Medical Center. Dr. DeBattista specializes in psychiatry with special expertise in clinical depression, disorders of excessive somnolence, electroconvulsive therapy, and fatigue.

SOURCE: CNS Response, Inc.

Posted in: Drug Trial News

Tags: , , , , , ,

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading